Effect of teriparatide on pregnancy and lactation-associated osteoporosis with multiple vertebral fractures.

Choe EY, Song JE, Park KH, Seok H, Lee EJ, Lim SK, Rhee Y

Journal of bone and mineral metabolism23 Nov 2011Cited by 60 (Europe PMC)

PMID22105654DOI10.1007/s00774-011-0334-0PepBankPUB-22105654

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneCase report or seriesEfficacy outcome
In three women with pregnancy and lactation-associated osteoporosis, back pain resolved immediately after a regimen of teriparatide, calcium carbonate and cholecalciferol was prescribed; lactation had been stopped at diagnosis.
In plain wordsIn three women, back pain went away soon after teriparatide with calcium and vitamin D was prescribed. Breastfeeding had also stopped.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBack pain
Study
n = 3
Comparator
Baseline
Outcome group
Pain · Musculoskeletal
Source sentences
Summary
The back pain immediately resolved.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the effect of teriparatide (TPTD), the human recombinant parathyroid hormone (1-34), for 18 months in three women with PLO.
Summary · context
Calcium carbonate, cholecalciferol, and TPTD were prescribed.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2210565401
02HumanNot a test of Teriparatide (PTH 1-34) aloneCase report or seriesEfficacy outcome
In women with pregnancy-associated osteoporosis, lumbar spine BMD increased during the combined teriparatide regimen compared with baseline.
In plain wordsSpine bone density increased during the combined regimen compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD
Study
n = 3
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD increase
14.5 to 25%
lumbar spine
Mean BMD increase
19.5%
lumbar spine
Source sentences
Summary
Bone mineral density (BMD) increased by 14.5-25.0% (mean 19.5%) at the lumbar spine and by 9.5-16.7% (mean 13.1%) at the femoral neck, after 18 months of treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the effect of teriparatide (TPTD), the human recombinant parathyroid hormone (1-34), for 18 months in three women with PLO.
Summary · context
Calcium carbonate, cholecalciferol, and TPTD were prescribed.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2210565402
03HumanNot a test of Teriparatide (PTH 1-34) aloneCase report or seriesEfficacy outcome
In women with pregnancy-associated osteoporosis, femoral neck BMD increased during the combined teriparatide regimen compared with baseline.
In plain wordsHip bone density increased during the combined regimen compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD
Study
n = 3
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD increase
9.5 to 16.7%
femoral neck
Mean BMD increase
13.1%
femoral neck
Source sentences
Summary
Bone mineral density (BMD) increased by 14.5-25.0% (mean 19.5%) at the lumbar spine and by 9.5-16.7% (mean 13.1%) at the femoral neck, after 18 months of treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the effect of teriparatide (TPTD), the human recombinant parathyroid hormone (1-34), for 18 months in three women with PLO.
Summary · context
Calcium carbonate, cholecalciferol, and TPTD were prescribed.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2210565403
04HumanNot a test of Teriparatide (PTH 1-34) aloneCase report or seriesEfficacy outcome
In women with pregnancy-associated osteoporosis, final Z scores nearly normalized during the combined teriparatide regimen.
In plain wordsBone density scores nearly normalized during the combined regimen in women with pregnancy-associated osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedFinal BMD Z scores
Study
n = 3
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The final Z scores in these PLO patients were nearly normalized.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the effect of teriparatide (TPTD), the human recombinant parathyroid hormone (1-34), for 18 months in three women with PLO.
Summary · context
Calcium carbonate, cholecalciferol, and TPTD were prescribed.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2210565404
05HumanNot a test of Teriparatide (PTH 1-34) aloneCase report or seriesSafety outcome
In women with pregnancy-associated osteoporosis, no further fractures occurred during the combined teriparatide regimen.
In plain wordsNo further fractures occurred during the combined regimen in women with pregnancy-associated osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableFurther fractures
Study
n = 3
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
BMD significantly improved after 18 months of treatment with TPTD without further fractures.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the effect of teriparatide (TPTD), the human recombinant parathyroid hormone (1-34), for 18 months in three women with PLO.
Summary · context
Calcium carbonate, cholecalciferol, and TPTD were prescribed.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2210565406
06HumanNot a test of Teriparatide (PTH 1-34) aloneCase report or seriesSafety outcome
In women previously treated with the combined teriparatide regimen for pregnancy-associated osteoporosis, two second pregnancies had no complications.
In plain wordsTwo women treated with the combined regimen had second babies without complications.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableSecond pregnancy complications
Study
n = 2
Outcome group
Adverse events · Reproductive and sexual health
Source sentences
Summary
Two women had a second baby without any complication.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the effect of teriparatide (TPTD), the human recombinant parathyroid hormone (1-34), for 18 months in three women with PLO.
Summary · context
Calcium carbonate, cholecalciferol, and TPTD were prescribed.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2210565405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.